Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Biosciences, Inc. on April 3, 2023, covering events occurring on March 31, 2023. The filing details a material refinancing of the Company's debt obligations.
Key Financial Metrics and Debt Structure
The filing does not provide revenue, profit, cash flow, or margin data. The primary financial event is the restructuring of the Company's debt:
- New Facility: Entered into a Credit Agreement for a single-advance Term Loan A facility with a principal amount of $150.0 million.
- Maturity: The new loan is scheduled to mature on March 31, 2028.
- Interest Rates:
- Alternate Base Rate borrowings: Alternate Base Rate plus a spread of 2.00% to 2.75% based on the Senior Secured Net Leverage Ratio.
- SOFR borrowings: Adjusted Term SOFR or Daily Simple SOFR plus a spread of 3.00% to 3.75% based on the Senior Secured Net Leverage Ratio.
- Collateral: Secured by substantially all assets of the Company and subsidiary guarantors.
- Prepayment Fee: The Company incurred a 2.00% prepayment fee on the outstanding principal balance of the terminated Existing Credit Agreement.
Material Changes Versus Prior Period
The Company terminated its Existing Credit Agreement (dated December 7, 2021) and repaid all outstanding indebtedness under that facility using the proceeds from the new $150.0 million Term Loan A and cash on hand. This action replaced the previous Term Loan B facility with a new Term Loan A facility extending the maturity date to 2028.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future performance. The Credit Agreement includes customary affirmative and negative covenants, financial covenants, representations, warranties, and events of default. The Company retains the option to request incremental term facilities subject to certain conditions.
Key Facts for Investor Verification
- Verify the exact amount of the prepayment fee incurred (2.00% of the prior outstanding balance) and its impact on immediate cash flow.
- Confirm the Company's current Senior Secured Net Leverage Ratio to determine the applicable interest rate spread within the defined ranges.
- Review the specific financial covenants in the attached Credit Agreement (Exhibit 10.1) to assess compliance risks.
- Assess the impact of the new debt maturity (2028) on the Company's long-term liquidity profile compared to the prior facility.